The PD-L1 inhibitor cemiplimab-rwlc became the first immunotherapeutic agent to produce a statistically and clinically significant survival benefit in recurrent or metastatic cervical cancer that progressed after first-line platinum-based chemotherapy. Here, CD274 is linked to cervical cancer.